These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. Shang Y; Huang EJ Brain Res; 2016 Sep; 1647():65-78. PubMed ID: 27033831 [TBL] [Abstract][Full Text] [Related]
24. An Intramolecular Salt Bridge Linking TDP43 RNA Binding, Protein Stability, and TDP43-Dependent Neurodegeneration. Flores BN; Li X; Malik AM; Martinez J; Beg AA; Barmada SJ Cell Rep; 2019 Apr; 27(4):1133-1150.e8. PubMed ID: 31018129 [TBL] [Abstract][Full Text] [Related]
25. The role of TDP-43 in the pathogenesis of ALS and FTLD. Baralle M; Buratti E; Baralle FE Biochem Soc Trans; 2013 Dec; 41(6):1536-40. PubMed ID: 24256250 [TBL] [Abstract][Full Text] [Related]
26. Impaired protein degradation in FTLD and related disorders. Götzl JK; Lang CM; Haass C; Capell A Ageing Res Rev; 2016 Dec; 32():122-139. PubMed ID: 27166223 [TBL] [Abstract][Full Text] [Related]
27. TAR DNA binding protein-43 and fused in sarcoma/translocated in liposarcoma protein in two neurodegenerative diseases. Wang XN; Cui LY Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Jun; 34(3):286-92. PubMed ID: 22776664 [TBL] [Abstract][Full Text] [Related]
28. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia. Jovičić A; Paul JW; Gitler AD J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014 [TBL] [Abstract][Full Text] [Related]
29. [FTLD/ALS as TDP-43 proteinopathies]. Ishihara T; Ariizumi Y; Shiga A; Yokoseki A; Sato T; Toyoshima Y; Kakita A; Takahashi H; Nishizawa M; Onodera O Rinsho Shinkeigaku; 2010 Nov; 50(11):1022-4. PubMed ID: 21921552 [TBL] [Abstract][Full Text] [Related]
30. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Mackenzie IR; Rademakers R Curr Opin Neurol; 2008 Dec; 21(6):693-700. PubMed ID: 18989115 [TBL] [Abstract][Full Text] [Related]
31. Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. Austin JA; Wright GS; Watanabe S; Grossmann JG; Antonyuk SV; Yamanaka K; Hasnain SS Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4309-14. PubMed ID: 24591609 [TBL] [Abstract][Full Text] [Related]
32. Frontotemporal dementia-linked P112H mutation of TDP-43 induces protein structural change and impairs its RNA binding function. Agrawal S; Jain M; Yang WZ; Yuan HS Protein Sci; 2021 Feb; 30(2):350-365. PubMed ID: 33151007 [TBL] [Abstract][Full Text] [Related]
33. Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD. Shenouda M; Zhang AB; Weichert A; Robertson J Adv Neurobiol; 2018; 20():239-263. PubMed ID: 29916022 [TBL] [Abstract][Full Text] [Related]
34. [Clinical and pathological spectrum of TDP-43 associated ALS]. Onodera O; Yokoseki A; Tan CF; Ishihara T; Nishiira Y; Toyoshima Y; Kakita A; Nishizawa M; Takahashi H Rinsho Shinkeigaku; 2010 Nov; 50(11):940-2. PubMed ID: 21921519 [TBL] [Abstract][Full Text] [Related]
35. TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. Qin H; Lim LZ; Wei Y; Song J Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18619-24. PubMed ID: 25503365 [TBL] [Abstract][Full Text] [Related]
36. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Pottier C; Bieniek KF; Finch N; van de Vorst M; Baker M; Perkersen R; Brown P; Ravenscroft T; van Blitterswijk M; Nicholson AM; DeTure M; Knopman DS; Josephs KA; Parisi JE; Petersen RC; Boylan KB; Boeve BF; Graff-Radford NR; Veltman JA; Gilissen C; Murray ME; Dickson DW; Rademakers R Acta Neuropathol; 2015 Jul; 130(1):77-92. PubMed ID: 25943890 [TBL] [Abstract][Full Text] [Related]
37. Phosphorylated and aggregated TDP-43 with seeding properties are induced upon mutant Huntingtin (mHtt) polyglutamine expression in human cellular models. Coudert L; Nonaka T; Bernard E; Hasegawa M; Schaeffer L; Leblanc P Cell Mol Life Sci; 2019 Jul; 76(13):2615-2632. PubMed ID: 30863908 [TBL] [Abstract][Full Text] [Related]
38. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other? Baloh RH Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957 [TBL] [Abstract][Full Text] [Related]
39. Role of selected mutations in the Q/N rich region of TDP-43 in EGFP-12xQ/N-induced aggregate formation. Budini M; Romano V; Avendaño-Vázquez SE; Bembich S; Buratti E; Baralle FE Brain Res; 2012 Jun; 1462():139-50. PubMed ID: 22406069 [TBL] [Abstract][Full Text] [Related]
40. ALS Mutations Disrupt Phase Separation Mediated by α-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain. Conicella AE; Zerze GH; Mittal J; Fawzi NL Structure; 2016 Sep; 24(9):1537-49. PubMed ID: 27545621 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]